RAD-150 (TLB-150): The Long-Acting RAD-140 Analog
Last updated: March 2026
RAD-150 (TLB-150) is an esterified analog of RAD-140 (Testolone), featuring a benzoate ester that extends half-life and improves plasma stability. It acts as an androgen receptor agonist with anabolic selectivity. A newer research chemical with extremely limited human data — all findings come from preclinical animal models.
🧪 Buy RAD-150 at Swiss Chems →Once daily oral
Extended by ester
Cleaved to RAD-140 in vivo
📋 On this page
How RAD-150 Works
RAD-150 is a prodrug of RAD-140. The benzoate ester attached to the parent molecule is hydrolyzed by endogenous esterases in the bloodstream, releasing active RAD-140. The result is the same core androgen receptor agonism as RAD-140, delivered with a longer, smoother pharmacokinetic profile.
RAD-150 carries a benzoate ester group attached to the RAD-140 base structure. After oral ingestion, plasma esterases cleave this ester bond, releasing free RAD-140 into circulation. This prodrug mechanism is the same strategy used with testosterone esters (enanthate, cypionate) to extend release kinetics without altering the active molecule's pharmacology.
The released RAD-140 binds the androgen receptor (AR) as a full agonist with high affinity. Unlike partial agonists (e.g., Andarine), RAD-140 fully activates AR-dependent transcription in target tissues. Animal studies of RAD-140 show a high anabolic-to-androgenic ratio — strong effects in muscle and bone with comparatively reduced prostate and scalp stimulation.
RAD-140's reported half-life is ~15-20 hours. The benzoate ester in RAD-150 is estimated to extend this to ~48 hours, though no peer-reviewed pharmacokinetic data in humans exists. The slower ester hydrolysis provides a more stable plasma concentration curve, theoretically reducing peak-trough fluctuations that may contribute to side effects or inconsistent tissue exposure.
AR agonism in skeletal muscle activates anabolic gene programs: increased protein synthesis, IGF-1 expression, satellite cell recruitment, and anti-catabolic signaling. RAD-140 animal data demonstrated significant lean mass preservation even in castrated rodent models, suggesting high tissue-selective potency. RAD-150 is presumed to share this profile once the ester is cleaved.
What Preclinical Studies Show
⚠️ All data below is from animal studies (primarily rodent and primate models of RAD-140, the parent compound). No peer-reviewed human clinical data exists for RAD-150 specifically. These figures are for research reference only.
Side Effects & Risks
Key Takeaways
- Esterified prodrug of RAD-140 — benzoate ester cleaved to active compound in vivo
- Parent RAD-140 has strong animal-model evidence for anabolic selectivity
- High anabolic:androgenic ratio in rodent studies (~90% anabolic, ~4% androgenic vs testosterone)
- Once-daily dosing is theoretically sufficient given extended estimated half-life
- Expect HPG axis suppression and testosterone reduction — monitor bloodwork
- RAD-140 has documented liver enzyme elevation in human case reports
- No peer-reviewed human pharmacokinetic data for RAD-150 exists
- True half-life in humans is uncharacterized — ~48hr is a projection
- Benzoate ester metabolism and any unique risks are unknown
- Long-term safety, carcinogenicity, and reproductive effects not studied
🛒 Recommended Products
Testing and monitoring supplies for SARM research.
Research-Grade Peptides
Third-party tested compounds with certificates of analysis. Used by researchers worldwide.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational purposes only. It is not medical advice. RAD-150 (TLB-150) is not FDA approved and is not intended for human use. All data referenced is from preclinical animal studies of the parent compound RAD-140 or theoretical ester pharmacokinetics. Do not use any research chemical without consulting a qualified medical professional.